Ignite Creation Date:
2024-07-17 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475755
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-28
Brief Title:
NeoadjuvantAdjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Organization Data
Organization:
Tang-Du Hospital
Class:
OTHER
Study ID:
NO202405-11
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tang-Du Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None